The inhibitory effect of dexamethasone on platelet-derived growth factor-induced vascular smooth muscle cell migration through up-regulating PGC-1α expression

Experimental Cell Research

Volumn 317, Issue 8, 2011, Pages 1083-1092

  Xu, Wei ^a,b   Guo, Ting ^a   Zhang, Yan ^a   Jiang, Xiaohong ^a   Zhang, Yongxian ^a   Zen, Ke ^a   Yu, Bo ^b   Zhang, Chen Yu ^a  

^a NANJING UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Dexamethasone; MAPK; Migration; PGC 1 ; VSMC

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; DEXAMETHASONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLATELET DERIVED GROWTH FACTOR; SMALL INTERFERING RNA; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; RESTENOSIS; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE;

RATTUS;

EID: 79953091968     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.10.006     Document Type: Article

References (42)

1. Chen M.S., John J.M., Chew D.P., Lee D.S., Ellis S.G., Bhatt D.L. Bare metal stent restenosis is not a benign clinical entity. Am. Heart J. 2006, 151:1260-1264.
2. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 2006, 48:2584-2591.
3. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007, 356:1009-1019.
4. Schwartz S.M. Smooth muscle migration in atherosclerosis and restenosis. J. Clin. Invest. 1997, 100:S87-89.
5. Reil T.D., Sarkar R., Kashyap V.S., Sarkar M., Gelabert H.A. Dexamethasone suppresses vascular smooth muscle cell proliferation. J. Surg. Res. 1999, 85:109-114.
6. Pross C., Farooq M.M., Angle N., Lane J.S., Cerveira J.J., Xavier A.E., Freischlag J.A., Law R.E., Gelabert H.A. Dexamethasone inhibits vascular smooth muscle cell migration via modulation of matrix metalloproteinase activity. J. Surg. Res. 2002, 102:57-62.
7. Berk B.C., Gordon J.B., Alexander R.W. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J. Am. Coll. Cardiol. 1991, 17:111B-117B.
8. Villa A.E., Guzman L.A., Chen W., Golomb G., Levy R.J., Topol E.J. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J. Clin. Invest. 1994, 93:1243-1249.
9. Poon M., Gertz S.D., Fallon J.T., Wiegman P., Berman J.W., Sarembock I.J., Taubman M.B. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis 2001, 155:371-380.
10. Pires N.M., Schepers A., van der Hoeven B.L., de Vries M.R., Boesten L.S., Jukema J.W., Quax P.H. Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. Cardiovasc. Res. 2005, 68:415-424.
11. Liu X., Huang Y., Hanet C., Vandormael M., Legrand V., Dens J., Vandenbossche J.L., Missault L., Vrints C., De Scheerder I. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter. Cardiovasc. Interv. 2003, 60:172-178. (discussion 179).
12. Jimenez-Valero S., Santos B., Pajin F., Canton T., Lazaro E., Moreu J., Hernandez G., Padial L.R. Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction. Catheter. Cardiovasc. Interv. 2007, 70:492-497.
13. Konig A., Leibig M., Rieber J., Schiele T.M., Theisen K., Siebert U., Gothe R.M., Klauss V. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. Am. Heart J. 2007, 153(979):e971-978.
14. Han S.H., Ahn T.H., Kang W.C., Oh K.J., Chung W.J., Shin M.S., Koh K.K., Choi I.S., Shin E.K. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study. Am. Heart J. 2006, 152(887):e881-887.
15. del Rincon I., O'Leary D.H., Haas R.W., Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 2004, 50:3813-3822.
16. Panoulas V.F., Douglas K.M., Stavropoulos-Kalinoglou A., Metsios G.S., Nightingale P., Kita M.D., Elisaf M.S., Kitas G.D. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:72-75.
17. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829-839.
18. Lin J., Handschin C., Spiegelman B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005, 1:361-370.
19. Handschin C., Spiegelman B.M. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 2006, 27:728-735.
20. Zhang Y., Liu C., Zhu L., Jiang X., Chen X., Qi X., Liang X., Jin S., Zhang P., Li Q., Wang D., Liu X., Zeng K., Zhang J., Xiang Y., Zhang C.Y. PGC-1alpha inhibits oleic acid induced proliferation and migration of rat vascular smooth muscle cells. PLoS One 2007, 2:e1137.
21. Kim H.J., Park K.G., Yoo E.K., Kim Y.H., Kim Y.N., Kim H.S., Kim H.T., Park J.Y., Lee K.U., Jang W.G., Kim J.G., Kim B.W., Lee I.K. Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells. Antioxid. Redox Signal. 2007, 9:301-307.
22. Zhu L., Sun G., Zhang H., Zhang Y., Chen X., Jiang X., Krauss S., Zhang J., Xiang Y., Zhang C.Y. PGC-1alpha is a key regulator of glucose-induced proliferation and migration in vascular smooth muscle cells. PLoS One 2009, 4:e4182.
23. Qu A., Jiang C., Xu M., Zhang Y., Zhu Y., Xu Q., Zhang C., Wang X. PGC-1alpha attenuates neointimal formation via inhibition of vascular smooth muscle cell migration in the injured rat carotid artery. Am. J. Physiol. Cell Physiol. 2009, 297:C645-653.
24. Jiang X., Zhang Y., Hou D., Zhu L., Xu W., Ding L., Qi X., Sun G., Liu C., Zhang J., Zen K., Xiang Y., Zhang C.Y. 17beta-Estradiol inhibits oleic acid-induced rat VSMC proliferation and migration by restoring PGC-1alpha expression. Mol. Cell. Endocrinol. 2010, 315:74-80.
25. Xiong S., Salazar G., San Martin A., Ahmad M., Patrushev N., Hilenski L., Nazarewicz R.R., Ma M., Ushio-Fukai M., Alexander R.W. PGC-1 alpha serine 570 phosphorylation and GCN5-mediated acetylation by angiotensin II drive catalase down-regulation and vascular hypertrophy. J. Biol. Chem. 2010, 285:2474-2487.
26. Knutti D., Kaul A., Kralli A. A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol. Cell. Biol. 2000, 20:2411-2422.
27. Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., Rudolph D., Schutz G., Yoon C., Puigserver P., Spiegelman B., Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001, 413:179-183.
28. Gordon D., Mohai L.G., Schwartz S.M. Induction of polyploidy in cultures of neonatal rat aortic smooth muscle cells. Circ. Res. 1986, 59:633-644.
29. Grotendorst G.R., Seppa H.E., Kleinman H.K., Martin G.R. Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:3669-3672.
30. Goetze S., Xi X.P., Kawano H., Gotlibowski T., Fleck E., Hsueh W.A., Law R.E. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 1999, 33:798-806.
31. Jawien A., Bowen-Pope D.F., Lindner V., Schwartz S.M., Clowes A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 1992, 89:507-511.
32. Pukac L., Huangpu J., Karnovsky M.J. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp. Cell Res. 1998, 242:548-560.
33. Zhan Y., Kim S., Izumi Y., Izumiya Y., Nakao T., Miyazaki H., Iwao H. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler. Thromb. Vasc. Biol. 2003, 23:795-801.
34. Yoon J.C., Puigserver P., Chen G., Donovan J., Wu Z., Rhee J., Adelmant G., Stafford J., Kahn C.R., Granner D.K., Newgard C.B., Spiegelman B.M. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001, 413:131-138.
35. Hanniman E.A., Lambert G., Inoue Y., Gonzalez F.J., Sinal C.J. Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha. J. Lipid Res. 2006, 47:2503-2514.
36. Ohashi N., Matsumori A., Furukawa Y., Ono K., Okada M., Iwasaki A., Miyamoto T., Nakano A., Sasayama S. Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2521-2526.
37. Izumi Y., Kim S., Namba M., Yasumoto H., Miyazaki H., Hoshiga M., Kaneda Y., Morishita R., Zhan Y., Iwao H. Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ. Res. 2001, 88:1120-1126.
38. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., Hsueh W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
39. Hsueh W.A., Law R.E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1891-1895.
40. Rinaldi B., Pieri L., Donniacuo M., Cappetta D., Capuano A., Domenici L., Carnuccio R., Romagnoli P., Filippelli A., Rossi F. Rosiglitazone reduces the inflammatory response in a model of vascular injury in rats. Shock 2009, 32:638-644.
41. Park J.Y., Bae M.A., Cheon H.G., Kim S.S., Hong J.M., Kim T.H., Choi J.Y., Kim S.H., Lim J., Choi C.H., Shin H.I., Kim S.Y., Park E.K. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem. Biophys. Res. Commun. 2009, 378:645-649.
42. Hoffmann R., Langenberg R., Radke P., Franke A., Blindt R., Ortlepp J., Popma J.J., Weber C., Hanrath P. Evaluation of a high-dose dexamethasone-eluting stent. Am. J. Cardiol. 2004, 94:193-195.